Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.

被引：0
|
作者：
Drilon, Alexander E.
Kummar, Shivaani
Lin, Jessica Jiyeong
Tan, Daniel Shao-Weng
Moreno, Victor
Leyvraz, Serge
Dubashi, Biswajit
Haresh, K. P.
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Shen, Lin
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Duke NUS Med Sch, Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[7] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[8] Charit Univ Med Berlin, Berlin, Germany
[9] Jawaharlal Inst Postgrade Med Educ & Res, Pondicherry, India
[10] All India Inst Med Sci AIIMS, New Delhi, India
[11] Bayer HealthCare Pharmaceut Inc, Basel, Switzerland
[12] Chrestos Concept GmbH & Co KG, Essen, Germany
[13] Bayer SpA, Milan, Italy
[14] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing Key Lab Carcinogenesis & Translat Res, State Key Lab Holist Integrat Management Gastroin, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8570
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
    Drilon, A. E.
    Xu, R-H.
    van Tilburg, C. M.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Geoerger, B.
    Zwaan, C. M.
    Lassen, U. N.
    Italiano, A.
    Kummar, S.
    McDermott, R. S.
    Burcoveanu, D-I.
    Neu, N.
    Brega, N.
    Laetsch, T.
    Hong, D. S.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S500 - S501
  • [32] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
  • [33] Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)
    Cabanillas, Maria E.
    Lin, Jessica Jiyeong
    Brose, Marcia S.
    McDermott, Raymond S.
    Almubarak, Mohammed
    Bauman, Jessica R.
    Casanova, Michela
    Kummar, Shivaani
    Lee, Se-Hoon
    Leyvraz, Serge
    Oh, Do-Youn
    Shen, Lin
    Norenberg, Ricarda
    Bernard-Gauthier, Vadim
    Mussi, Chiara E.
    Hong, David S.
    Drilon, Alexander E.
    Waguespack, Steven G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
    Perreault, Sebastien
    Spano, Jean-Philippine
    Nilsson, Anna
    Deyell, Rebecca J.
    Doz, Francois
    Geoerger, Birgit
    Gumus, Mahmut
    Lassen, Ulrik N.
    Nysom, Karsten
    Valero-Arrese, Lorena
    Idbaih, Ahmed
    Bernard-Gauthier, Vadim
    Neu, Natascha
    Brega, Nicoletta
    Drilon, Alexander
    Laetsch, Theodore W.
    van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2024, 26
  • [35] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
    Brose, M. S.
    Shen, L.
    Tan, D. S. W.
    Kummar, S.
    Lin, J. J.
    McDermott, R.
    Berlin, J.
    Tahara, M.
    Lassen, U. N.
    Leyvraz, S.
    Patel, J. D.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Hong, D. S.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S600 - S601
  • [36] Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
    Moreno, V.
    Lin, J. J.
    Tan, D. S. W.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Rudolph, M.
    Norenberg, R.
    Schulz, A.
    Fellous, M.
    Brega, N.
    Shen, L.
    Kummar, S.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S60 - S60
  • [37] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Perreault, Sebastien
    Drilon, Alexander
    Lassen, Ulrik N.
    Geoerger, Birgit
    Nysom, Karsten
    Ora, Ingrid
    Gavrilovic, Igor T.
    Norenberg, Ricarda
    Bernard-Gauthier, Vadim
    De la Cuesta, Esther
    Laetsch, Theodore W.
    Doz, Francois
    Van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2022, 24 : 87 - 87
  • [38] Activity of larotrectinib in TRK fusion lung cancer
    Drilon, A.
    Kummar, S.
    Moreno, V.
    Patel, J.
    Lassen, U.
    Rosen, L.
    Childs, B. H.
    Nanda, S.
    Cox, M. C.
    Ku, N. C.
    Farago, A. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TRK FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN UPDATED ANALYSIS
    Perreault, Sebastien
    Doz, Francois
    Deyell, Rebecca J.
    Kebudi, Rejin
    Nilsson, Anna
    Nysom, Karsten
    Geoerger, Birgit
    Zhang, Yi-Zhuo
    Bernard-Gauthier, Vadim
    Neu, Natascha
    de la Cuesta, Esther
    Laetsch, Theodore W.
    van Tilburg, Cornelis M.
    NEURO-ONCOLOGY, 2024, 26
  • [40] Activity of Larotrectinib in TRK Fusion Lung Cancer
    Farago, A.
    Kummar, S.
    Moreno, V.
    Patel, J.
    Lassen, U.
    Rosen, L.
    Ku, N.
    Cox, M.
    Nanda, S.
    Childs, B.
    Hyman, D.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S283 - S284
12345